Make an enquiry
Refer a patient
HCP Logout

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
Make an enquiry
Refer a patient

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor

Lymphoma

Lymphoma
2025-02-21T00:00:00.000+11:00
Ongoing

BGB-11417-302

BGB-11417-302
Lymphoma

Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients with Relapsed/Refractory Mantle Cell Lymphoma.

Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients with Relapsed/Refractory Mantle Cell Lymphoma.

Trial overview

Clinical Area

Haematology

Disease

Lymphoma

Disease site

Malignant Haematology

Study Phase

III

Trial Identifiers

Registration number: NCT06742996

https://clinicaltrials.gov/study/NCT06742996

GenesisCare Location(s)
Principal Investigator(s)
Haematologist

Dr David Kliman

MBBS (Hons), FRACP, FRCPA

Dr David Kliman
location pin icon

North Shore

View Profile
Profile Image - Dr David Kliman

Clinical trials enquiries

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.


 

Disclaimer:

This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.